The UCL-Cytiva Centre of Excellence (CoE) at the Department of Biochemical Engineering marked a significant milestone today, celebrating a decade of impactful collaboration and charting a bold future focused on advanced, personalised medicines.
The event highlight was the unveiling of a commemorative plaque, symbolising the long-standing partnership and Cytiva’s ongoing commitment to joint research and innovation. Celebrating the continued success was Amanda Chmura, Deputy Director of Business and Impact Partnerships, representing the EPSRC Prosperity Partnership, which co-funds the 'Smart biomanufacturing for personalised medicines.'
Furthermore, the ceremony welcomed two leading figures from Cytiva, Richard Gutman (Distinguished Fellow) and Rick Morris (Distinguished fellow - Technology, Innovation and Strategy Group), as they officially joined UCL's faculty as Honorary Professors of the Department of Biochemical Engineering. Their appointments solidify a critical bridge between academic discovery and industrial application, collectively ensuring rapid research translation into real-world biomanufacturing solutions, which solve industry challenges.
"Today, we are pleased to recognise a decade-long partnership and a true collaborative research model that has succeeded by combining academic innovation with industrial risk-taking, supported by EPSRC. We are proud to be supporting the early careers of over 26 future bioprocess leaders, with over 145 publications and conference presentations of novel research and development knowledge, which is transforming the Bioprocess Industry," said Professor Dan Bracewell, Director of the UCL-Cytiva CoE. “As we look ahead to the next CoE phase, the next decade will focus on scaling our efforts to tackle the most complex manufacturing challenges in personalised and next-generation therapeutics.”
“Our UCL-Cytiva Centre of Excellence embodies UCL’s vision of harnessing innovative research and integrating industrial expertise to accelerate the delivery of life-saving, personalised medicines and secure UK leadership in advanced biomanufacturing”. Geraint Rees, VP for Research, Innovation & Global Engagement, UCL
“Cytiva, part of the Danaher Corporation, is a global leader in the provision of technologies and services that advance and accelerate the development and manufacture of diagnostic tests, therapeutics and vaccines. We are proud to actively collaborate with UCL to support the life-science industry, and to see Rick and Richard’s dedication to research and teaching officially recognised.” Ed Hoare, Vice President and General Manager, Filtration, Cytiva.
About the UCL-Cytiva Centre of Excellence
The UCL-Cytiva Centre of Excellence is a long-standing partnership focused on developing and implementing cutting-edge bioprocess technologies to accelerate the development and manufacture of life-saving medicines. Get in touch or link in with us on LinkedIn.
